SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as a high-stakes binary battlefield, with investors closely monitoring the Phase 3 REGAL trial data and imminent survival event disclosures while short sellers face intensifying pressure from significant interest and elevated borrow rates. Community discourse centers on a potential short squeeze and buyout speculation, as retail traders debate the clinical implications of the trial's duration and its broader potential as a cancer treatment platform.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential Russell 1000 index inclusion, driving significant options activity and a high-volume surge that has intensified the ongoing conflict between bullish market participants and short sellers. Investors are closely watching for follow-through momentum and potential catalysts, including upcoming Q2 earnings and international clinical milestones, as they look to capitalize on the recent price action.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is seeing significant volatility driven by passive index fund rebalancing as the stock transitions between Russell indices, while broader investor sentiment remains bullish due to its role in powering high-demand AI data centers. Community discussion is heavily focused on the stock's long-term utility in solving power infrastructure bottlenecks versus short-term technical price swings caused by mechanical institutional trading.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is seeing renewed investor attention as the community focuses on its AI-driven credit underwriting as a potential infrastructure play, despite ongoing frustration with the stock's recent volatility and sensitivity to macro headwinds. Discussions are dominated by speculation over a potential short squeeze, upcoming product catalysts, and comparisons to other fintech peers in the sector.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent expansion that secures exclusivity for its flagship drug, MIPLYFFA, through 2041. The community is actively discussing this move as a major catalyst that bolsters the company's long-term valuation and serves as a primary point of interest for potential M&A suitors.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility and intense social media chatter as market participants react to the rapidly evolving geopolitical tensions between the U.S. and Iran. The community remains deeply divided, with many actively debating whether the recurring cycles of escalation and sudden diplomatic de-escalation are genuine developments or strategic market manipulation designed to influence sentiment ahead of the holiday week.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense market debate as investors weigh the impact of institutional accumulation against concerns regarding potential liquidation risks tied to large corporate holdings. The community remains deeply divided, with bulls pointing to strong long-term holder resolve and potential regulatory catalysts, while bears focus on technical breakdowns and broader macroeconomic volatility.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending as investors weigh strong institutional support and a series of analyst price target hikes against broader market volatility and concerns over energy grid demand. The community remains divided, with supporters pointing to long-term infrastructure contracts and AI data center expansion, while skeptics focus on potential short-term stock manipulation and power rate concerns in local communities.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending due to anticipation surrounding its ongoing commercial rollout of Rezdiffra and significant investor interest in potential M&A scenarios involving major industry players. Community sentiment remains mixed, with bullish supporters highlighting the company's first-mover advantage and pipeline expansion, while others debate the impact of high R&D spending and the competitive threat from emerging MASH treatments.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to positive Phase 3 trial data for its gene therapy candidate, sparking community discussions about a potential short squeeze given the stock's high short interest. The conversation is largely focused on the company's progress toward commercialization, a strengthened cash runway, and the ongoing sector-wide rotation into gene editing.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quanterix Stock Is Popping In Pre-Market: Here's Why

Quanterix shares surged 5.28% in pre-market trading on Wednesday to $3.39, reversing the prior day's losses.read more...

TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today 

Equity

The small-cap stocks surged between 6% and 27% after hours on Tuesday. 


Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the Inducement Grants) were made to three employees in connection with...

Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Companys new Chief Financial Officer, effective June 22. Faessler brings extensive finance...

Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterixs...

Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June...

Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the Inducement Grant) was made to Anthony Catalano in connection with...

Quanterix Announces Planned Transition of Chief Financial Officer

Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (CFO) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will...

Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -25.81% and -0.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Releases Financial Results for the First Quarter of 2026

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the first quarter...

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Quanterix Corp

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

QTRXQuanterix Corp

Fundamentals

Latest QTRX News